CT-101 (Carmell Therapeutics)

N/A

Report date: 2025/05/30 14:54:06

Base Information

Drug NameCT-101 (Carmell Therapeutics)
Drug Alias NameTibia fracture treatmentLong-bone fracture treatmentCT101
ClassificationBiologics
Mechanisms of ActionFibroblast growth factors stimulants
TargetsFibroblast growth factors
Therapy Area/IndicationsFractures, Bone
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesCarnegie Mellon University
China Registration ClassN/A

Develop Information

Active CompaniesCarnegie Mellon UniversityCarmell Therapeutics Co
Inactive CompaniesN/A
Active IndicationsFractures, Bone
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A